Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

If you’re on the fence about investing in Sanofi or Novartis AG because you ... and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In ...

If you’re on the fence about investing in Amgen Inc., Amgen Inc., Amgen Inc., Amgen Inc. or Sanofi because you ... medicines for diabetes and cardiovascular diseases; and established prescription ...

However, this is increasingly being shadowed by a growing incidence of lifestyle-related diseases such as hypertension, diabetes and ... Remaining MNCs include Sanofi Aventis (#13th Rank ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott Diabetes Care and Bayer having a ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.